The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

被引：0
|
作者：
George T. Grossberg
Facundo Manes
Ricardo F. Allegri
Luis Miguel Gutiérrez-Robledo
Sergio Gloger
Lei Xie
X. Daniel Jia
Vojislav Pejović
Michael L. Miller
James L. Perhach
Stephen M. Graham
机构：
[1] Saint Louis University School of Medicine,Department of Neurology and Psychiatry
[2] Instituto de Neurología Cognitiva (INECO),undefined
[3] Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI),undefined
[4] Instituto de Geriatría,undefined
[5] Institutos Nacionales de Salud de México,undefined
[6] PsicoMedica Clinical and Research Group,undefined
[7] Forest Research Institute,undefined
[8] Prescott Medical Communications Group,undefined
来源：
CNS Drugs | 2013年 / 27卷
关键词：
Memantine; Cholinesterase Inhibitor; Semantic Fluency; Verbal Fluency Test; Severe Impairment Battery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 478
页数：9
相关论文
共 31 条
  • [21] Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
    John M Ringman
    Sally A Frautschy
    Edmond Teng
    Aynun N Begum
    Jenny Bardens
    Maryam Beigi
    Karen H Gylys
    Vladimir Badmaev
    Dennis D Heath
    Liana G Apostolova
    Verna Porter
    Zeba Vanek
    Gad A Marshall
    Gerhard Hellemann
    Catherine Sugar
    Donna L Masterman
    Thomas J Montine
    Jeffrey L Cummings
    Greg M Cole
    Alzheimer's Research & Therapy, 4
  • [22] Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Xu, YK
    Ieni, JR
    Schwam, EM
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 20 (06) : 559 - 569
  • [23] The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, randomized, placebo-controlled trial
    Zheng, Huaguang
    Wang, Yilong
    Wang, Anxin
    Li, Hao
    Wang, David
    Zhao, Xingquan
    Wang, Penglian
    Shen, Haipeng
    Zuo, Lijun
    Pan, Yuesong
    Li, Zixiao
    Meng, Xia
    Wang, Xianwei
    Shi, Weixiong
    Ju, Yi
    Liu, Liping
    Dong, Kehui
    Wang, Chunxue
    Sui, Rubo
    Xue, Rong
    Pan, Xiaoping
    Niu, Xiaoyua
    Luo, Benyan
    Sui, Yi
    Wang, Huali
    Feng, Tao
    Wang, Yongjun
    SCIENCE BULLETIN, 2019, 64 (02) : 101 - 107
  • [24] Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
    Grossberg, George T.
    Alva, Gustavo
    Hendrix, Suzanne
    Ellison, Noel
    Kane, Mary C.
    Edwards, John
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2018, 32 (03) : 173 - 178
  • [25] Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
    Mecocci, Patrizia
    Bladstroem, Anna
    Stender, Karina
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 24 (05) : 532 - 538
  • [26] A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD)
    Ballard, Clive
    Thomas, Alan
    Gerry, Stephen
    Yu, Ly-Mee
    Aarsland, Dag
    Merritt, Claire
    Corbett, Anne
    Davison, Christopher
    Sharma, Narenda
    Khan, Zunera
    Creese, Byron
    Loughlin, Paul
    Bannister, Carol
    Burns, Alistair
    Win, Soe Nyunt
    Walker, Zuzana
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2015, 16 (04) : 316 - 322
  • [27] Sustained Effects of Once-Daily Memantine Treatment on Cognition and Functional Communication Skills in Patients with Moderate to Severe Alzheimer's Disease: Results of a 16-Week Open-Label Trial
    Schulz, Joerg B.
    Rainer, Michael
    Kluenemann, Hans-Hermann
    Kurz, Alexander
    Wolf, Stefanie
    Sternberg, Kati
    Tennigkeit, Frank
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (03) : 463 - 475
  • [28] Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease
    Lane, Hsien-Yuan
    Wang, Shi-Heng
    Lin, Chieh-Hsin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2023, 77 (02) : 102 - 109
  • [29] Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial
    Homma, Akira
    Atarashi, Hirotsugu
    Kubota, Naoki
    Nakai, Kenya
    Takase, Takao
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 52 (01) : 345 - 357
  • [30] Adjunctive transcranial direct current stimulation (tDCS) plus sodium benzoate for the treatment of early-phase Alzheimer's disease: A randomized, double-blind, placebo-controlled trial
    Lane, Hsien-Yuan
    Wang, Shi-Heng
    Lin, Chieh-Hsin
    PSYCHIATRY RESEARCH, 2023, 328
1234